Halogen Patents (Class 424/1.85)
-
Patent number: 7863047Abstract: New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection.Type: GrantFiled: April 25, 2008Date of Patent: January 4, 2011Assignee: Provectus Pharmatech, Inc.Inventors: H. Craig Dees, Timothy C. Scott, Eric A. Wachter, Walter G. Fisher, John Smolik
-
Patent number: 7858072Abstract: This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.Type: GrantFiled: December 19, 2005Date of Patent: December 28, 2010Assignee: The Trustees of the University of PennsylvaniaInventors: Hank F. Kung, Mei-Ping Kung, Zhi-Ping Zhuang
-
Patent number: 7858803Abstract: The present invention relates to compounds and methods for imaging and treating Alzheimer's disease or an amyloidosis-associated pathological condition that utilize a novel amyloid imaging tracer for detecting amyloid deposits in a subject suffering from these conditions. In certain embodiments, the invention relates to [N-2[18F]fluoropropyl]-2-(4?-(methylamino)-phenyl)-6-hydroxybenzothiazole (F-18MHT) and dimers thereof.Type: GrantFiled: April 28, 2008Date of Patent: December 28, 2010Assignee: The General Hospital CorporationInventors: David R. Elmaleh, Timothy M. Shoup, Alan J. Fischman
-
Patent number: 7854920Abstract: This invention relates to novel thioflavin derivatives, methods of using the derivatives in, for example, in vivo imaging of patients having neuritic plaques, pharmaceutical compositions comprising the thioflavin derivatives and method of synthesizing the compounds. The compounds find particular use in the diagnosis and treatment of patients having diseases where accumulation of neuritic plaques are prevalent. The disease states or maladies include but are not limited to Alzheimer's disease, familial Alzheimer's disease, Down's Syndrome and homozygotes for the apolipoprotein E4 allele.Type: GrantFiled: July 26, 2007Date of Patent: December 21, 2010Assignee: University of PittsburghInventors: William E. Klunk, Chester A. Mathis, Jr., Yanming Wang
-
Patent number: 7850948Abstract: This invention relates to new radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy. The radiohalogenated benzamide derivatives according to the invention exhibit novel and especially advantageous properties, in particular with respect to tumor concentration and retardation, liver concentration and blood accumulation. The radiation-therapy doses to be achieved in the tumor, compared to healthy body tissue, are advantageous for the compounds according to the invention.Type: GrantFiled: September 10, 2008Date of Patent: December 14, 2010Assignee: Bayer Schering Pharma AGInventors: Matthias Friebe, Peter Muschick, Andreas Huth
-
Patent number: 7846419Abstract: A method for producing radioactive isotopes for positron emission tomography is provided. The method includes generating radioactive isotopes by the acceleration of a projectile in a linear accelerator that is operative to accelerate at least two different projectiles.Type: GrantFiled: December 14, 2006Date of Patent: December 7, 2010Assignee: Siemens AktiengesellschaftInventors: Sven Fritzler, Peter Schardt, Stefan Setzer
-
Publication number: 20100303719Abstract: The present invention relates to anti-cancer compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides analogs of the known anti-cancer compound amonafide, and structurally and functionally related compounds, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with hyperproliferation.Type: ApplicationFiled: January 12, 2009Publication date: December 2, 2010Applicant: NORTHWESTERN UNIVERSITYInventors: Sui Huang, John Norton, Daniel Appella, Mark Witschi
-
Patent number: 7842278Abstract: The invention features a class of 2-nitroimidazole compounds with a secondary basic nitrogen atom and a linker bearing one or more therapeutic agents, cytotoxic agents, detectable labels, or chelating groups. In particular, the invention provides 2-nitroimidazole compounds containing a cluster of boron atoms for use in boron neutron capture therapy (BNCT). The 2-nitroimidazole compounds can be used to treat hypoxic conditions, including, e.g., cancer, inflammation, and ischemia. The weakly basic 2-nitroimidazole compounds target to hypoxic tissue and provide increased tissue concentration overall.Type: GrantFiled: October 27, 2006Date of Patent: November 30, 2010Assignee: Natural Pharmacia International, Inc.Inventors: David Y-W Lee, Xiao-Shen Ji, James A. Raleigh
-
Patent number: 7837981Abstract: Provided herein are agents that bind to soluble beta-amyloid. Also provided are in vivo and in vitro methods for detecting soluble beta-amyloid in a sample that may include brain tissue.Type: GrantFiled: December 11, 2006Date of Patent: November 23, 2010Assignee: General Electric CompanyInventors: Tiberiu Mircea Siclovan, Michael Christopher Montalto, Kenneth Michael Fish, Eric Dustin Agdeppa, Cristina Tan Hehir
-
Patent number: 7837982Abstract: The present invention provides novel amino acid compounds useful in detecting and evaluating brain and body tumors. These compounds have the advantageous properties of rapid uptake and prolonged retention in tumors and can be labeled with halogen isotopes such as fluorine-18, iodine-123, iodine-124, iodine-125, iodine-131, bromine-75, bromine-76, bromine-77, bromine-82, astatine-210, astatine-211, and other astatine isotopes. These compounds can also be labeled with technetium and rhenium isotopes using known chelation complexes. The compounds disclosed herein bind tumor tissues in vivo with high specificity and selectivity when administered to a subject. Preferred compounds show a target to non-target ratio of at least 2:1, are stable in vivo and substantially localized to target within 1 hour after administration. Preferred compounds include 1-amino-2-[18F]fluorocyclobutyl-1-carboxylic acid (2-[18F]FACBC) and 1-amino-2-[18F]fluoromethylcyclobutyl-1-carboxylic acid (2-[18F]FMACBC).Type: GrantFiled: June 19, 2006Date of Patent: November 23, 2010Assignee: Emory UniversityInventor: Mark M. Goodman
-
Publication number: 20100284914Abstract: Novel families of amine-borane compounds, including fluorinated aminoboranes, novel bis-aminoboranes and aminoboranes having saturated and unsaturated ling alkyl chains are provided. Processes of preparing, pharmaceutical compositions and methods utilizing these novel compounds are also provided. Radiolabeled aminoboranes and uses thereof in radioimaging (e.g., PET) and radiotherapy are further provided.Type: ApplicationFiled: September 13, 2006Publication date: November 11, 2010Applicants: Yissum Research Development Company of the Hebrew University of Jerusalem, Soreq Nuclear Research Center Israel Atomic Energy CommissionInventors: Morris Srebnik, Khuloud Takrouri, Eli Shalom
-
Patent number: 7820144Abstract: Disclosed are cannabimimetic aminoalkylindole compounds and methods for their manufacture. The disclosed compounds are surprisingly potent and selective cannabinoids. The disclosed compounds may include radioactive atoms. Also disclosed are methods of using the disclosed compounds, including use of the disclosed compounds to stimulate a cannabinoid receptor, to provide a physiological effect in an animal or individual, to treat a condition in an animal or individual and for use in radioimaging.Type: GrantFiled: January 5, 2007Date of Patent: October 26, 2010Assignee: University of ConnecticutInventors: Alexandros Makriyannis, Hongfeng Deng
-
Patent number: 7815894Abstract: Compounds, compositions and methods for the diagnosis of Alzheimer's disease. Synthesized Glycerophosphocholine (GPC) may be used as a diagnostic aid to measure progression of Alzheimer's disease. GPC is a membrane phospholipid metabolite that is capable of binding specifically to the ?-turn of beta amyloid (A?) peptide. Compounds including non-radioactive, paramagnetic, and radioactive derivatives of GPC are presented. These compounds possess similar binding properties to original GPC molecules and are useful in medical magnetic resonance imaging and/or positron emission tomography applications. By employing these radiological techniques in conjunction with the compositions of the present invention, the diagnosis and assessment of the progression of Alzheimer's disease may be achieved.Type: GrantFiled: May 27, 2004Date of Patent: October 19, 2010Inventors: Jay W. Pettegrew, Richard J. McClure, Kanagasabai Panchalingam, Billy W. Day
-
Patent number: 7807135Abstract: This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.Type: GrantFiled: December 19, 2005Date of Patent: October 5, 2010Assignee: The Trustees of the University of PennsylvaniaInventors: Hank F. Kung, Mei-Ping Kung, Zhi-Ping Zhuang
-
Patent number: 7799947Abstract: The invention relates to a compound of formula (I) having use for in vivo imaging of the NR2B subtype of the NMDA receptor.Type: GrantFiled: November 28, 2006Date of Patent: September 21, 2010Assignee: Hammersmith Imanet LimitedInventors: Erik Arstad, Gjermund Henriksen
-
Patent number: 7790142Abstract: The present invention relates to novel modified fatty acid analogs, where a positron or gamma-emitting label is placed at a position on a fatty acid backbone and an organic substituent is substituted at the 2,3; 3,4; 4,5; 5,6 and other sequence positions of a fatty acid backbone. These novel fatty acid analogs are designed to enter the tissues of interest by the same long chain fatty acid carrier mechanism as natural fatty acids, however, functional substituents in the 2,3; 3,4; 4,5; 5,6 and other sequence positions, block the catabolic pathway, thus trapping these analogs in a virtually unmodified form in the tissues of interest.Type: GrantFiled: October 11, 2007Date of Patent: September 7, 2010Assignee: The General Hospital CorporationInventors: David R. Elmaleh, Alan J. Fischman, Timothy M. Shoup
-
Patent number: 7790141Abstract: Radio-opaque biodegradable compositions are formed by modifying terminal groups of synthetic and natural biodegradable polymers such as polylactones with iodinated moieties. The biodegradable property of the compositions renders them suitable for use in medical field such as drug delivery, imaging. Compounds disclosed in this invention exist as neat liquid. Certain compositions disclosed in this invention form hydrophobic iodine rich domains when dissolved in water, such domains provide better contrasting properties as well as ability to dissolve hydrophobic bioactive drugs. Certain iodinated moieties disclosed in the invention are capable of cross linking natural proteins in situ in presence of suitable catalysts and co-catalysts.Type: GrantFiled: August 9, 2004Date of Patent: September 7, 2010Assignee: Pathak Holdings, LLCInventors: Chandrashekhar P. Pathak, Sanjay M. Thigle
-
Publication number: 20100221180Abstract: A molecular probe for labeling myelin includes a fluorescent stilbenzene derivative.Type: ApplicationFiled: September 2, 2008Publication date: September 2, 2010Inventors: Yanming Wang, Chunying Wu
-
Publication number: 20100221181Abstract: The present invention relates to a method of differentially diagnosing different types of dementia. In particular, the method relates to the use of specific SPECT tracers for differentially diagnosing Alzheimer's disease, Lewy-Body Dementia, and Frontotemporal Dementia.Type: ApplicationFiled: September 23, 2008Publication date: September 2, 2010Applicant: KONINKLIJKE PHILIPS ELECTRONICS N.V.Inventor: Frank Olaf Thiele
-
Patent number: 7785566Abstract: The invention comprises pharmaceuticals of formula (I) Z-(L)n-V, wherein V denotes a peptide, L denotes an optional linker, Z denotes a group that optionally can carry an imaging moiety M, n denotes 0 or 1. The pharmaceuticals are active as therapeutic agents for the treatment of heart failure, cardiac arrhythmias and diseases were fibrosis is prominent such as COPD, liver fibrosis and atherosclerosis and are also useful as diagnostic agents for the diagnosis of heart failure and diseases were fibrosis is prominent such as COPD, liver fibrosis and atherosclerosis.Type: GrantFiled: November 5, 2004Date of Patent: August 31, 2010Assignee: GE Healthcare, Inc.Inventors: Alan Cuthbertson, Bard Indrevoll, Morten Eriksen
-
Patent number: 7776311Abstract: The present invention provides compounds of the formula X—R1-D-[Dpr, Orn or Lys](A)-R2(Z)-D-[Dpr, Orn or Lys](B)—R3(Y)—NR4R5; or R1(X)-D-[Dpr, Orn or Lys](A)-R2(Z)-D-[Dpr, Orn or Lys](B)—R3(Y)—NR4R5, in which X is a hard acid cation chelator, a soft acid cation chelator or Ac-, R1, R2 and R3 are independently selected from a covalent bond or one or more D-amino acids that can be the same or different, Y is a hard acid cation chelator, a soft acid cation chelator or absent, Z is a hard acid cation chelator, a soft acid cation chelator or absent, and A and B are haptens or hard acid cation chelators and can be the same or different, and R4 and R5 are independently selected from the group consisting of hard acid cation chelators, soft acid cation chelators, enzymes, therapeutic agents, diagnostic agents and H. The present invention also provides methods of using these compounds and kits containing the compounds.Type: GrantFiled: December 18, 2006Date of Patent: August 17, 2010Assignee: Immunomedics, Inc.Inventors: William J. McBride, David M. Goldenberg
-
Publication number: 20100178248Abstract: The present invention relates to the use of a specific compound, as described in detail below, having a high affinity to the peripheral benzodiazepine receptor for imaging cardiac and cardiovascular diseases for which inflammation and/or mitochondrial dysfunction and any other pathophysiological process leading to PBR activation are major contributing factor.Type: ApplicationFiled: May 21, 2008Publication date: July 15, 2010Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFTInventors: Andrea Thiele, Claudia Bacher-Stier
-
Publication number: 20100143253Abstract: The present invention provides compounds and amyloid probes thereof that allow for an antemortem method of diagnosing AD and quantitating the extent or progression of amyloid deposits (plaques) by in vivo imaging of amyloid and/or amyloid deposits in the regions of the brain. Preferably, an amyloid probe of the invention can cross the blood-brain barrier and distinguish AD brain from normal brain. An amyloid probe can be administered to a patient in amounts suitable for in vivo imaging of amyloid deposits. Amyloid probes of the invention can also be used to detect and quantitate amyloid deposits in diseases including, without limitation, Down's syndrome, familial AD and homozygotes for the apolipoprotein E4 allele. In one aspect, the compounds may be used in the treatment or prophylaxis of diseases that include, without limitation, AD and type 2 diabetes mellitus.Type: ApplicationFiled: February 17, 2010Publication date: June 10, 2010Inventors: Gilles D. Tamagnan, David Alagille, Herve Da Costa
-
Publication number: 20100135903Abstract: The present invention relates generally to a method of treating a neoplastic condition and to agents useful for same. More particularly, the present invention is directed to a method of facilitating the treatment of a metastatic neoplastic tumour in a localised manner by effecting the exposure of neoplastic cell intra-cellular molecules, preferably intra-nuclear molecules, suitable for use as a therapeutic target. The co-localisation of tumour cells and metastases to discrete tissue locations thereby renders the method of the present invention useful in terms of the delivery of bystander-based therapy.Type: ApplicationFiled: October 11, 2007Publication date: June 3, 2010Applicant: MEDVET SCIENCE PTY. LTD.Inventors: Michael Paul Brown, Fares Al-Ejeh, Jocelyn Margaret Darby
-
Patent number: 7727511Abstract: Provided herein are agents that bind to soluble beta-amyloid. Also provided are in vivo and in vitro methods for detecting soluble beta-amyloid in a sample that may include brain tissue.Type: GrantFiled: December 11, 2006Date of Patent: June 1, 2010Assignee: General Electric CompanyInventors: Tiberiu Mircea Siclovan, Michael Christopher Montalto, Tun Chiao Hubert Lam, Eric Dustin Agdeppa, Amy Casey Williams, Cristina Tan Hehir
-
Publication number: 20100119447Abstract: A radiolabeled lymphatic staining agent is mixed on site with a much larger amount, on a weight basis, of a non-radiolabeled lymphatic staining agent to form an injectable radiolabeled lymphatic staining agent suitable for surgical use in humans. Preferably, the radiolabel is I-125, because it has a 60-day half-life which enables it to be made off-site. The preferred radiolabeled lymphatic staining agent is iodinated methylene blue, because it can be mixed with a range of non-radioactive lymphatic staining agents, for example isosulfan blue, methylene blue, patent blue, and patent blue V, to provide the injected agent with sufficient radioactivity to enable machine detection. A method for making radioiodinated methylene blue is also disclosed.Type: ApplicationFiled: August 29, 2009Publication date: May 13, 2010Inventors: Thomas J. Maloney, Arthur E. Camp, JR., Jesse J. Hernandez
-
Publication number: 20100098633Abstract: Novel radiopharmaceuticals that are useful in diagnostic imaging and therapeutic treatment of disease characterized by overexpression of seprase include complexes that contains a proline moiety and a radionuclide adapted for radioimaging and/or radiotherapy:Type: ApplicationFiled: September 24, 2009Publication date: April 22, 2010Inventors: Craig ZIMMERMAN, John W. Babich, John Joyal, John Marquis, Jian-cheng Wang
-
Patent number: 7700075Abstract: The present invention provides agents and methods for dual modality virtual colonoscopy that gives both anatomical and functional information using hybrid CT/PET scanning. In preferred embodiments, the present invention provides radiolabeled tumor-specific agents and methods for distinguishing benign polyps from malignant tumors. In further embodiments, the present invention provides compositions and methods useful for distinguishing morphological and functional subregions of a selected region of tissue based on relative levels of phospholipid metabolism. Preferred radiolabeled tumor-specific agents are phospholipid ether analogs labeled with a halogen radioisotope. In certain preferred embodiments, the compositions including radiolabeled phospholipid ether analogs have therapeutic actions in addition to functionally identifying malignant tissue.Type: GrantFiled: July 8, 2005Date of Patent: April 20, 2010Assignee: Cellectar, LLCInventors: Jamey P. Weichert, Marc Longino
-
Publication number: 20100092387Abstract: A compound that has affinity with amyloid, exhibits sufficiently rapid clearance from normal tissues, and is suppressed in toxicity such as mutagenicity is provided, which is represented by the following formula (1): or a salt thereof, wherein R1 is a group selected from hydrogen, hydroxyl group, carboxyl group, sulfate group, amino group, nitro group, cyano group, an alkyl substituent with one to 4 carbon atoms or an alkoxy substituent with one to 4 carbon atoms; R2 is a radioactive halogen substituent; and m is an integer of 0 to 2, and a low-toxic diagnostic agent for Alzheimer's disease comprising a compound represented by the above formula or a salt thereof is also provided.Type: ApplicationFiled: June 21, 2007Publication date: April 15, 2010Applicants: NIHON MEDI-PHYSICS CO., LTD., GE HEALTHCARE LIMITEDInventors: Shigeyuki Tanifuji, Akio Hayashi, Daisaku Nakamura, Shinya Takasaki, Storey Anthony Eamon, Denis Raymond Christophe Bouvet
-
Publication number: 20100068140Abstract: The present invention relates to methods for the detection of myelin and a quantitative measurement of its local concentration in a sample using a benzofuran compound or its radioisotope derivatives. In one embodiment a method of myelin detection comprises identifying a subject at risk of or diagnosed with a myelin-associated neuropathy, parenterally administering to the subject the benzofuran compound, or a derivative of the compound, and determining myelination in the subject by detecting binding in the sample. In one embodiment, the invention provides a method of imaging myelinated tissue in a surgical field of mammalian tissue comprising the steps of contacting the surgical site with the benzofuran compound or a radioisotope derivative of the compound, and detecting binding in the surgical site.Type: ApplicationFiled: September 17, 2008Publication date: March 18, 2010Applicant: GENERAL ELECTRIC COMPANYInventors: Christina Abucay Tan Hehir, Stephen Johnson Lomnes, Kenneth Michael Fish, Tiberiu Mircea Siclovan, Michael Christopher Montalto, Tunchiao Hubert Lam
-
Publication number: 20100034741Abstract: The present invention relates to radiolabelled compounds particularly 1-azabicyclo[2.2.2]octane compounds (i.e., quinuclidine compounds) which are labeled with one or more radioisotopes and which are suitable for imaging or therapeutic treatment of tissues, organs, or tumors which express the ?7-nicotinic cholinergic receptor. In another embodiment, the invention relates to methods of imaging tissues, organs, or tumors using radiolabeled compounds of the invention, particularly tissues, organs, or tumors which express ?7-nicotinic cholinergic receptor to which the compounds of the invention have an affinity.Type: ApplicationFiled: January 26, 2009Publication date: February 11, 2010Applicants: The Johns Hopkins UniversityInventors: Martin G. Pomper, John L. Musachio, Hong Fan, Robert F. Dannals, Catherine Foss, Eifion Phillips, John Gordon, Dennis McCarthy, Richard Keith, Mark Smith, Richard Heys, Peter N. Dorff
-
Patent number: 7658910Abstract: According to a first aspect of the invention, a process is disclosed for the preparation of radiolabelled haloaromatic compounds. According to a second aspect of the invention, intermediate precursor insoluble polymer compounds used in the preparation of the radiolabelled haloaromatics are disclosed, as well as processes for the preparation of the intermediate precursor insoluble polymer compounds.Type: GrantFiled: September 5, 2007Date of Patent: February 9, 2010Assignee: The University of Western OntarioInventors: Duncan H. Hunter, Xizhen Zhu
-
Publication number: 20100003192Abstract: In one aspect, the present invention provides a method of treating breast cancer that is negative for at least one of ER, PR, or HER2, comprising administering to a subject at least one PARP inhibitor. In another aspect, the present invention provides a method of treating breast cancer comprising administering to a subject at least one PARP inhibitor in combination with at least one anti-tumor agent.Type: ApplicationFiled: July 1, 2009Publication date: January 7, 2010Applicant: BiPar Sciences, Inc.Inventors: Barry M. Sherman, Charles Bradley, Valeria S. Ossovskaya
-
Publication number: 20090317327Abstract: The invention relates to an aqueous dispersion of superparamagnetic iron-containing particles bearing ?-hydroxycarboxylic acids as stabilizer substances on their surface, said dispersion comprising N-methyl-D-glucamine (meglumine) and/or 2-amino-2-(hydroxymethyl)-1,3-propanediol (trometamol) and the content of free iron ions being lower than 1 mg of iron per liter. In a preferred embodiment the dispersion according to the invention may additionally include an iron-complexing agent. In another preferred embodiment the dispersion includes positively charged metal ions and/or compounds containing polyamino groups, which can be bound to substances having a therapeutic or diagnostic effect. The invention is also directed to a method of producing said dispersion, the use thereof as an MRT contrast medium as well as the use thereof as therapeutic agent, including the option of therapy follow-up using an imaging method.Type: ApplicationFiled: December 7, 2006Publication date: December 24, 2009Applicant: FERROPHARM GMBHInventor: Herbert Pilgrimm
-
Publication number: 20090311179Abstract: The invention relates to a method of selectively targeting an active agent (or agent capable of becoming an active agent) to apoptotic cells in a vertebrate, comprising administering to said vertebrate a system comprising an arsenoxide (or arsenoxide equivalent) compound and said agent, wherein said system selectively targets apoptotic cells.Type: ApplicationFiled: April 30, 2009Publication date: December 17, 2009Applicant: NEW SOUTH INNOVATIONS PTY LIMITEDInventor: Philip John Hogg
-
Patent number: 7632485Abstract: One aspect of the present invention relates to a method of preparing radiofluorinated substituted alkyl, cycloalkyl, aryl, and alkenyl compounds. In a preferred embodiment, potassium fluoride-18 is used. Another aspect of the invention relates to piperazine compounds containing fluorine-18 that are useful as imaging agents. In certain embodiments, the piperazine compounds contain a quaternary amine. Another aspect of the invention relates to arylphosphonium compounds containing fluorine-18 that are useful as imaging agents. In certain embodiments, the phosphonium compound is a tetraaryl phosphonium salt. Another aspect of the present invention relates to a method of obtaining a positron emission image of a mammal, comprising the steps of administering to a mammal a compound of the invention, and acquiring a positron emission spectrum of the mammal.Type: GrantFiled: February 24, 2005Date of Patent: December 15, 2009Assignee: Massachusetts General HospitalInventors: David R. Elmaleh, Alan J. Fischman, Timothy M. Shoup
-
Publication number: 20090304587Abstract: The present invention discloses composites which generally comprise a polymeric matrix and a hydrophobic organic compound which is associated with a radioisotope.Type: ApplicationFiled: November 1, 2006Publication date: December 10, 2009Applicants: Yissum Research Development Company Of The Hebrew University of Jerusalem, Hadasit Medical Research Services & Development LimitedInventors: Abraham Rubinstein, Abdel Kareem Azab, Boris Orkin, Aviram Nissan, Susan Haupt, Morris Srebnki, Raphael Udassin
-
Publication number: 20090297446Abstract: A diagnostic formulation is provided comprising a tropane having a radioactive concentration of at least 1.6 mCi/mL at least about 51 hours post creation. The diagnostic formulation optionally comprises a radiolabeled dopamine transporter (DAT) ligand useful in the diagnosis of Parkinson's disease (PS). One example of a radiolabeled dopamine transporter (DAT) ligand example is [123I]-2?-carbomethoxy-3?-(4-flurophenyl)-N-(3-iodo-E-allyl) nortropane.Type: ApplicationFiled: March 24, 2009Publication date: December 3, 2009Applicant: Alseres Pharmaceuticals, Inc.Inventors: Chris Sterzinger, Cara Ferreira, David Leyh, Richard Thorn
-
Publication number: 20090285755Abstract: The present invention discloses a method for the enzyme-mediated, site-specific, in-vivo precipitation of a water soluble molecule in an animal. The enzyme is either unique to tumor cells, or is produced within a specific site (e.g., tumor) at concentrations that are higher than that in normal tissues. Alternatively, the enzyme is conjugated to a targeting moiety such as an antibody or a receptor-binding molecule.Type: ApplicationFiled: April 3, 2009Publication date: November 19, 2009Applicant: President and Fellows of Harvard CollegeInventors: Amin I. Kassis, Ravi S. Harapanhalli
-
Patent number: 7612206Abstract: Novel benzamide compounds of Formula (I), Formula (II), and Formula (III), salts, water soluble salts, analogs and radiolabeled counterparts thereof as sigma-2 receptor radiotracers for imaging the proliferative status of solid tumors. A method for diagnosing a mammal for the presence of a mammalian tumor therein comprises administering to the mammal a diagnostic imaging detectable effective amount of a benzamide compound having a structure illustrated in Formula (I), Formula (II) and Formula (III) and detecting binding of the compound to a tumor in the mammal. A method for diagnostic imaging of a mammalian tissue having cell surface sigma-2 receptors comprising administering to a mammal a diagnostic imaging amount of a compound having a structure illustrated in Formula (I) Formula (II) and Formula (III) and detecting an image of a tissue having an ample cells with sigma-2 receptors.Type: GrantFiled: March 8, 2008Date of Patent: November 3, 2009Assignee: Washington UniversityInventors: Robert Mach, Michael J. Welch, Douglas J. Rowland, Zhude Tu
-
Publication number: 20090263321Abstract: Effective treatments of pain that accompanies post-operative surgeries are provided. Through the administration of an effective amount of a combination of bupivacaine and clonidine at or near a target site, one can alleviate or prevent pain. This administration of bupivacaine and clonidine or pharmaceutically acceptable salts thereof is particularly useful following surgery.Type: ApplicationFiled: April 8, 2009Publication date: October 22, 2009Applicants: Warsaw Orthopedic, Inc., Medtronic, Inc.Inventors: Phillip E. McDonald, Amira Wohabrebbi, Christopher M. Hobot, Vanja M. King
-
Publication number: 20090252680Abstract: A compound represented by the following formula or a salt thereof: wherein each of A1, A2, A3 and A4 independently represents a carbon or nitrogen; R1 is a group selected from the group consisting of hydrogen, hydroxyl group, carboxyl group, sulfuric acid group, amino group, nitro group, cyano group, non-radioactive halogen substituents, alkyl substituents with 1-4 carbon atoms and alkoxy substituents with 1-4 carbon atoms; and R2 is a radioactive halogen substituent, provided at least one of A1, A2, A3 and A4 represents a carbon, and R1 binds to a carbon represented by A1, A2, A3 or A4, is effective as an image diagnosis probe targeting amyloid and as well as a diagnostic agent for Alzheimer's disease including the compound represented by the above formula or a salt thereof.Type: ApplicationFiled: October 30, 2007Publication date: October 8, 2009Applicant: NIHON- MEDI-PHYSICS CO., LTDInventors: Shigeyuki Tanifuji, Daisaku Nakamura, Shinya Takasaki, Yuki Okumura
-
Publication number: 20090252679Abstract: The present invention provides a compound which has affinity with amyloid, shows sufficiently rapid clearance from normal tissues and is suppressed in toxicity such as mutagencity. Provided is a compound represented by the following formula (1) or a salt thereof: wherein A1, A2, A3 and A4 independently represents a carbon or nitrogen; R1 is a halogen substituent; R2 is a halogen substituent; and m is an integer of 0 to 2, provided that at least one of R1 and R2 is a radioactive halogen substituent, at least one of A1, A2, A3 and A4 represents a carbon, and R1 binds to a carbon represented by A1, A2, A3 or A4 as well as a low-toxic diagnostic agent comprising a compound represented by the preceding formula or a salt thereof.Type: ApplicationFiled: May 15, 2007Publication date: October 8, 2009Applicant: NIHON MEDI-PHYSICS CO., LTD.Inventors: Shigeyuki Tanifuji, Daisaku Nakamura, Shinya Takasaki, Yuki Okumura
-
Patent number: 7597876Abstract: The present application discloses compositions and methods of synthesis and use of F-18 labeled molecules of use, for example, in PET imaging techniques. In particular embodiments, the labeled molecules may be peptides or proteins, although other types of molecules including but not limited to aptamers, oligonucleotides and nucleic acids may be labeled and utilized for such imaging studies. In preferred embodiments, the F-18 label may be conjugated to a targeting molecule by formation of a metal complex and binding of the F-18-metal complex to a chelating moiety, such as DOTA, NOTA, DTPA, TETA or NETA. In other embodiments, the metal may first be conjugated to the chelating group and subsequently the F-18 bound to the metal. In other preferred embodiments, the F-18 labeled moiety may comprise a targetable conjugate that may be used in combination with a bispecific or multispecific antibody to target the F-18 to an antigen expressed on a cell or tissue associated with a disease, medical condition, or pathogen.Type: GrantFiled: December 19, 2007Date of Patent: October 6, 2009Assignee: Immunomedics, Inc.Inventors: William J. McBride, David M. Goldenberg
-
Publication number: 20090238760Abstract: Hexahydroindenopyridine compounds are disclosed which act as contraceptive agents by disrupting spermatogenesis, acting as spermicides or sperm motility inhibitors and/or act as antifungals; antispermatogenic, sperm motility inhibitors, spermicidal or antifungal compositions containing the compounds; and methods for disrupting spermatogenesis, inhibiting sperm motility, killing motile sperm or treating fungi using the compounds and compositions. Also disclosed are radioactive compounds which may be used to study the binding of antifertility compounds to specific sites in the body and the use of such compounds for that purpose.Type: ApplicationFiled: April 19, 2007Publication date: September 24, 2009Applicant: Research Triangle InstituteInventors: Clarence Edgar Cook, Kevin M Cook, Clyde Ray Tallent, Brian Frazier Thomas, Hernan Andres Navarro
-
Publication number: 20090238759Abstract: To provide a method of rapid methylation of alkenes, which is applicable to the preparation of a PET tracer and which enables alkenes to be methylated through cross coupling between SP2 (alkenyl) and SP3 (alkyl) carbon atoms rapidly and in a high yield. Methyl iodide and an alkenyltrialkylstannane are subjected to cross coupling in an aprotic polar solvent in the presence of a palladium complex having a valence of 0, a phosphine ligand, a cuprous halide, and a carbonate and/or alkali metal fluoride.Type: ApplicationFiled: October 6, 2006Publication date: September 24, 2009Applicant: GIFU UNIVERSITYInventors: Masaaki Suzuki, Takamitsu Hosoya
-
Patent number: 7575738Abstract: The present invention relates to the use of Heat Shock Proteins and fragments thereof as targeting ligand. The Heat Shock Protein may be labeled with imaging agents that are capable of binding lectin-like oxidized low-density lipoprotein (LOX-1) or may be attached to a therapeutic agent. The sequences are useful for the diagnosis and monitoring of diseases as well as means for internalizing signaling moieties and therapeutics.Type: GrantFiled: August 13, 2004Date of Patent: August 18, 2009Assignee: General Electric CompanyInventors: Faisal A. Syud, Ming Zhao, Andrew S. Torres
-
Publication number: 20090191125Abstract: Piperidine or piperazine compounds useful for treating neurodegenerated diseases characterized by the lack of dopamine neurons activity or for imaging the dopamine neurons are provided.Type: ApplicationFiled: April 9, 2008Publication date: July 30, 2009Applicant: The General Hospital CorporationInventors: David R. Elmaleh, Choi Sungwoon, Alan J. Fischman
-
Publication number: 20090169475Abstract: Methods of imaging tissue of a mammal which expresses chymase include administering to the mammal an effective amount of a radiolabeled chymase inhibitor.Type: ApplicationFiled: December 18, 2008Publication date: July 2, 2009Inventors: John W. Babich, William C. Eckelman, John Joyal, Craig Zimmerman
-
Publication number: 20090162283Abstract: To provide a diagnostic drug which binds specifically to an amyloid aggregate and/or an amyloid deposit, to thereby realize imaging and quantification of a disease caused by amyloid aggregation and/or deposition. The invention provides a compound represented by formula (1): (wherein X1 represents an optionally substituted bicyclic heterocyclic group; X2 represents a hydrogen atom, a halogen atom, or a chelate-forming group; ring A represents a benzene ring or a pyridine ring; and ring B represents an optionally substituted 5-membered aromatic heterocyclic group which is bonded to the benzene ring or the pyridine ring via a carbon atom of ring B), a salt thereof, a solvate of any of these, or a transition metal coordination compound of any of these, and a diagnostic, preventive, or therapeutic drug containing the same.Type: ApplicationFiled: November 30, 2006Publication date: June 25, 2009Applicants: Fujifilm RI Pharma Co., Ltd., Daiichi Sankyo Company, LimitedInventors: Kazunori Bando, Kazumi Taguchi